David S Salomon

List of Publications by Year
in descending order

77 papers	3,280 citations	101543 36 h-index	161849 54 g-index
78 all docs	78 docs citations	78 times ranked	2709 citing authors

#	Article	IF	Citations
1	Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. Journal of Clinical Investigation, 2003, 112, 575-587.	8.2	136
2	Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. Molecular Carcinogenesis, 1989, 2, 1-11.	2.7	135
3	Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTVâ€Criptoâ€1 transgenic mice. Journal of Cellular Physiology, 2004, 201, 266-276.	4.1	126
4	Role of Cripto-1 in Stem Cell Maintenance and Malignant Progression. American Journal of Pathology, 2010, 177, 532-540.	3.8	110
5	Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha-transforming growth factors inras-transformed mouse mammary epithelial cells. Journal of Cellular Physiology, 1987, 130, 397-409.	4.1	101
6	Differential immunohistochemical detection of transforming growth factor Î±, amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95
7	A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Research, 2003, 63, 1192-7.	0.9	91
8	Cripto-1 Enhances Migration and Branching Morphogenesis of Mouse Mammary Epithelial Cells. Experimental Cell Research, 2001, 266, 95-105.	2.6	87
9	The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition. Seminars in Cancer Biology, 2014, 29, 51-58.	9.6	86
10	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Journal of Clinical Investigation, 2014, 124, 3003-3015.	8.2	84
11	Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer. Breast Cancer Research and Treatment, 2016, 156, 211-226.	2.5	80
12	Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. Clinical Cancer Research, 2006, 12, 5158-5164.	7.0	79
13	Role of Human Cripto-1 in Tumor Angiogenesis. Journal of the National Cancer Institute, 2005, 97, 132-141.	6.3	76
14	Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on the growth inhibitory and increased phosphatidylinositol (PI) responses induced by epidermal growth factor (EGF) in A431 cells. Journal of Cellular Physiology, 1983, 117, 91-100.	4.1	72
15	Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene, 2005, 24, 4094-4105.	5.9	70
16	Cripto-1: An Oncofetal Gene with Many Faces. Current Topics in Developmental Biology, 2005, 67, 85-133.	2.2	70
17	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-Î± genes on in vitro transformation of human mammary epithelial cells. Molecular Carcinogenesis, 1992, 6, 43-52.	2.7	65
18	Expression of cripto, a Novel Gene of the Epidermal Growth Factor Family, in Human Gastrointestinal Carcinomas. Japanese Journal of Cancer Research, 1991, 82, 969-973.	1.7	64

#	Article	IF	Citations
19	Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration. Journal of Biological Chemistry, 2007, 282, 31643-31655.	3.4	60
20	Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells <i>In vitro</i> and <i>In vivo</i>. Cancer Prevention Research, 2019, 12, 147-158.	1.5	58
21	Cripto-1 Is a Cell Surface Marker for a Tumorigenic, Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells Â. Stem Cells, 2010, 28, 1303-1314.	3.2	57
22	<i>Cripto-1</i> as a novel therapeutic target for triple negative breast cancer. Oncotarget, 2015, 6, 11910-11929.	1.8	57
23	Overexpression of Human Cripto-1 in Transgenic Mice Delays Mammary Gland Development and Differentiation and Induces Mammary Tumorigenesis. American Journal of Pathology, 2005, 167, 585-597.	3.8	54
24	Cripto-1 Is Required for Hypoxia to Induce Cardiac Differentiation of Mouse Embryonic Stem Cells. American Journal of Pathology, 2009, 175, 2146-2158.	3.8	54
25	Stromal influences on transformation of human mammary epithelial cells overexpressingc-myc and SV40T. Journal of Cellular Physiology, 1990, 145, 207-216.	4.1	53
26	Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. International Journal of Cancer, 2000, 88, 566-574.	5.1	53
27	Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. Journal of Cell Biology, 2009, 187, 343-353.	5.2	52
28	Requirement of Glycosylphosphatidylinositol Anchor of Cripto-1 for trans Activity as a Nodal Co-receptor. Journal of Biological Chemistry, 2007, 282, 35772-35786.	3.4	51
29	Characterization of Cancer Stem-Like Cells Derived from Mouse Induced Pluripotent Stem Cells Transformed by Tumor-Derived Extracellular Vesicles. Journal of Cancer, 2014, 5, 572-584.	2.5	51
30	Basic Science Review: Growth Factors in Cancer and Their Relationship to Oncogenes. Cancer Investigation, 1986, 4, 43-60.	1.3	50
31	Processing and juxtacrine activity of membrane-anchored betacellulin. Journal of Cellular Biochemistry, 1999, 72, 423-434.	2.6	49
32	An evolving web of signaling networks regulated by Cripto-1. Growth Factors, 2012, 30, 13-21.	1.7	49
33	Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. , 1996, 15, 44-56.		48
34	Site-selective 8-chloroadenosine 3â€²,5â€²-cyclic monophosphate inhibits transformation and transforming growth factor Î± production in Ki-ras-transformed rat fibroblasts. FEBS Letters, 1989, 242, 363-367.	2.8	45
35	Cripto-1 enhances the canonical Wnt/Î²-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cellular Signalling, 2013, 25, 178-189.	3.6	45
36	mRNA Expression of Transforming Growth Factor Alpha in Human Breast Carcinomas and Its Activity in Effusions of Breast Cancer Patients. Journal of the National Cancer Institute, 1989, 81, 1165-1171.	6.3	42

#	Article	IF	Citations
37	Regulation of human criptoâ€1 gene expression by TGFâ€î²1 and BMPâ€4 in embryonal and colon cancer cells. Journal of Cellular Physiology, 2008, 215, 192-203.	4.1	42
38	Selenophosphate synthetase 1 is an essential protein with roles in regulation of redox homoeostasis in mammals. Biochemical Journal, 2016, 473, 2141-2154.	3.7	37
39	Purification and Characterization of a Recombinant Human Cripto-1 Protein. Growth Factors, 1998, 15, 215-229.	1.7	36
40	Î²-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. Biochemical and Biophysical Research Communications, 2007, 355, 240-244.	2.1	36
41	Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an Estrogen-independent phenotype. International Journal of Cancer, 1990, 46, 712-718.	5.1	33
42	Identification of Cripto-1 in human milk. Breast Cancer Research and Treatment, 2001, 66, 1-7.	2.5	32
43	Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation. PLoS ONE, 2014, 9, e107976.	2.5	32
44	TIMP-2 suppresses tumor growth and metastasis in murine model of triple-negative breast cancer. Carcinogenesis, 2020, 41, 313-325.	2.8	32
45	Infection with a transforming growth factor Î± anti-sense retroviral expression vector reduces thein vitro growth and transformation of a human colon cancer cell line. International Journal of Cancer, 1993, 54, 952-958.	5.1	31
46	Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. International Journal of Cancer, 1995, 62, 762-766.	5.1	31
47	Regulation of human Criptoâ€1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. Journal of Cellular Physiology, 2013, 228, 1174-1188.	4.1	30
48	Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis. , 1997, 170, 47-56.		28
49	Localization of estrone sulfatase in human breast carcinomas. Breast Cancer, 1999, 6, 331-337.	2.9	27
50	RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. International Journal of Cancer, 2000, 88, 44-52.	5.1	26
51	Netrinâ€1 can affect morphogenesis and differentiation of the mouse mammary gland. Journal of Cellular Physiology, 2008, 216, 824-834.	4.1	24
52	CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget, 2015, 6, 11994-12008.	1.8	20
53	Transformation of mouse mammary epithelial cells with the Ha-rasbut not with theneuoncogene results in a gene dosage-dependent increase in transforming growth factor-Î± production. FEBS Letters, 1989, 250, 474-478.	2.8	18
54	Characterization of a novel amphiregulin-related molecule in 12-O-tetradecanoylphorbol-13-acetate-treated breast cancer cells. , 1996, 169, 497-508.		18

#	Article	IF	Citations
55	Tumor-associated macrophages derived from cancer stem cells. Acta Histochemica, 2020, 122, 151628.	1.8	18
56	Expression and Function of Egf-Related Peptides and Their Receptors in Gynecological Cancer - From Basic Science to Therapy?. Journal of Receptor and Signal Transduction Research, 2000, 20, 1-46.	2.5	17
57	Flat revertants derived from kirsten murine sarcoma virus-transformed cells produce transforming growth factors. Journal of Cellular Physiology, 1984, 121, 22-30.	4.1	16
58	Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells. , 1998, 176, 383-391.		15
59	Intercellular transfer regulation of the paracrine activity of GPI-anchored Cripto-1 as a Nodal co-receptor. Biochemical and Biophysical Research Communications, 2010, 403, 108-113.	2.1	12
60	Cripto-1: an extracellular protein â€“ connecting the sequestered biological dots. Connective Tissue Research, 2015, 56, 364-380.	2.3	12
61	Different pancreatic cancer microenvironments convert iPSCs into cancer stem cells exhibiting distinct plasticity with altered gene expression of metabolic pathways. Journal of Experimental and Clinical Cancer Research, 2022, 41, 29.	8.6	11
62	Early dysregulation of cripto-1 and immunomodulatory genes in the cerebral cortex in a macaque model of neuroAIDS. Neuroscience Letters, 2006, 410, 94-99.	2.1	10
63	Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model. International Journal of Molecular Sciences, 2018, 19, 3345.	4.1	10
64	Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human Mammary epithelial cells. Journal of Cellular Physiology, 2001, 186, 233-242.	4.1	9
65	Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy. Cancers, 2021, 13, 2491.	3.7	9
66	Characterization of the glycosylphosphatidylinositol-anchor signal sequence of human Cryptic with a hydrophilic extension. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2671-2681.	2.6	8
67	Cripto-1 Ablation Disrupts Alveolar Development in the Mouse Mammary Gland through a Progesterone Receptorâ€“Mediated Pathway. American Journal of Pathology, 2015, 185, 2907-2922.	3.8	8
68	Mouse induced pluripotent stem cell microenvironment generates epithelial-mesenchymal transition in mouse Lewis lung cancer cells. American Journal of Cancer Research, 2014, 4, 80-8.	1.4	8
69	Adaptation of Laser Microdissection Technique for the Study of a Spontaneous Metastatic Mammary Carcinoma Mouse Model by NanoString Technologies. PLoS ONE, 2016, 11, e0153270.	2.5	7
70	Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient. Journal of Microencapsulation, 2016, 33, 172-182.	2.8	6
71	Transforming Growth Factor Â in Cancer: Janus, the Two-Faced God. Journal of the National Cancer Institute, 2014, 106, djt441-djt441.	6.3	5
72	Whence CRIPTO: The Reemergence of an Oncofetal Factor in â€˜Woundsâ€™ That Fail to Heal. International Journal of Molecular Sciences, 2021, 22, 10164.	4.1	4

#	Article	IF	Citations
73	Cripto-1 in TNBC. Aging, 2015, 7, 515-516.	3.1	2
74	Optimization of production and characterization of a recombinant soluble human Criptoâ€1 protein inhibiting selfâ€renewal of cancer stem cells. Journal of Cellular Biochemistry, 2022, , .	2.6	2
75	Differential immunohistochemical detection of transforming growth factor Î±, amphiregulin and CRIPTO in human normal and malignant breast tissues. International Journal of Cancer, 1996, 65, 51-56.	5.1	1
76	Antiâ€"sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cellâ€"adhesion and tumorigenicity in ovarian cancer cells. , 2000, 88, 566.		1
77	TIMPâ€2 Inhibits Triple Negative Breast Cancer Growth and Metastasis through EMT Suppression and Promotion of Vascular Normalization. FASEB Journal, 2018, 32, 678.2.	0.5	1